Regulatory guidelines are in place across the world to ensure that approval of antibiotics is consistent with current scientific understanding of quality, efficacy and safety including minimizing the risk of the development of antibiotic resistance. We suggest the regulatory process is fit for purpose and does indeed approve products that are safe for use with regard to development of antibiotic resistance. However, we maintain that in order to preserve the longevity of antibiotics, treatment should be based on an established diagnosis and normally only antibiotics authorized for the diagnosed indication and indicated bacteria are used. Furthermore, susceptibility testing should be carried out whenever possible. Despite a general acceptance that antibiotic resistance is a significant issue, antibiotics can still receive a marketing authorization without a sponsor having to generate a clinical breakpoint. The consequence of this is that for many antibiotics we have no measure of what is resistant and what is susceptible at the approved dose. We argue that the time is right for all approvals of new or existing antibiotics to have independently agreed clinical breakpoints, as part of the regulatory process, without which talk of resistance is somewhat meaningless. This is relevant not only for novel antibiotics but also for generic compounds.
Introduction
Antibiotics, like all veterinary medicinal products, are regulated on the basis of safety, efficacy and quality. In Europe and indeed across most parts of the world regulatory guidelines are in place and updated as necessary, to ensure that the approval of licensed products is consistent with current scientific understanding. In Europe, this is primarily covered by three guidance documents (Anon 2004 (Anon , 2005 (Anon , 2016a . The guidance addressing antibiotic resistance is summarized within the document commonly known as the summary of product characteristics (Anon 2005) where it clearly addresses all the necessary information making it possible to use the veterinary medicinal product effectively and safely while at the same time minimizing the risk of development of antibiotic resistance. The document indicates items considered relevant from this point of view that should be addressed by the drug sponsor and also states that elements of prudent use should be included and presents examples of how this can be achieved. We have largely used the term, 'antibiotic' as opposed to 'antimicrobial' resistance although when citing other documents where reference is made to 'antimicrobials' we have used the latter term, this in itself illustrates the inconsistency in terminology in this challenging area.
The regulatory environment thus addresses the challenges posed by antimicrobial resistance development and prudent use guidance. A question that must therefore be posed is to ask whether the current regulatory guidance is fit for purpose. This paper addresses this question, however, when considering any aspect of prudent use we must always keep in mind the principle that bacterial infections, both in humans and in animals, should always be treated with the best-suited antibiotics according to scientific criteria.
Regulation is not the only controlling factor
In addition to the current regulatory framework there are a number of bodies considering the complex issues surrounding antimicrobial use. The World Health Organisation-Advisory Group on Integrated Surveillance of Antimicrobial Resistance (WHO-AGISAR) has been active in determination of the significance of antibiotic classes for the therapy of infectious bacterial diseases in humans (WHO, 2012 (WHO, , 2013 . According to the criteria defined, the antibiotic classes are divided into the categories critically important antimicrobials (CIA), highly important antimicrobials and important antimicrobials. In the category of critically important there are 15 classes, in the second category 13 classes and in the last category 4 classes. The WHO-AGISAR document also lists examples of substances from the various classes that are used exclusively in veterinary medicine. Table 1 gives an overview of the WHO-AGISAR classification. For veterinary medicine, the World Organisation for Animal Health (OIE) has drawn up a corresponding list with veterinary critically important, veterinary highly important and veterinary important antimicrobials (OIE, 2014) , last revised in January 2014. This OIE list is summarized in Table 2 .
At the end of 2014, at the request of the European Commission, the European Medicines Agency (EMA) classified the CIA and some highly important antimicrobials from the WHO list according to their risk for humans from resistance selection in veterinary medicine (EMA, 2014) . Three categories were established, as follows:
Category 1: classes used in veterinary medicine, for which the risk for public health is viewed as low or limited. Category 2: classes used in veterinary medicine, for which the risk is viewed as higher. Category 3: antibiotic classes, which are not used in veterinary medicine.
For category 1, it was recommended that any inappropriate use should stop and treatment of animal groups should be restricted as much as possible. For category 2, it was recommended that they should only be used if there are no other effective alternatives. Substances from category 3 are not authorized in veterinary medicine and accordingly they have no maximum residue level and can therefore only be used in justified exceptional cases for nonfood-producing animals. The EMA classification is summarized in Table 3 .
What becomes clear from these respective listings is that there is a series of overlaps in the use of critically important antibiotics in human and veterinary medicine and that many of these classes are of great importance for both human and veterinary medicine in treating infectious bacterial diseases. Important and a point often overlooked is that many of the modern classes of critically important antibiotics used in human medicine are not authorized for veterinary medicine (see Table 1 ).
Case study-use of antibiotics of last resort in human and veterinary medicine in Germany
The definition of reserve antibiotics in Germany for human medicine refers to their use in outpatient therapy (Schr€ oder et al. 2005 ; Schr€ oder 2011a). These antibiotics should only be used when standard antibiotics are not effective or in the case of life-threatening diseases. Standard and reserve antibiotics according to this definition are contrasted in Table 4 . In Germany, a trend of increased use of reserve antibiotics has been seen for many years in outpatient therapy of infectious diseases. In 1991, about 11% of all prescriptions were for reserve The consumption rates of antibiotics in veterinary medicine in Germany were published for the year 2013 by the Bundesamt f€ ur Verbraucherschutz und Lebensmittelsicherheit, the German regulatory authority for veterinary medicines (Anon 2014) ). According to the German definition of reserve antibiotics (Table 4) , only 3% of the antibiotics used in veterinary medicine fall into this category, and barely 10% of that belong to the four critically important WHO-AGISAR classes. Of this 10%, 89% are macrolides, 8% are quinolones and 3% are third-and fourth-generation cephalosporins. The less frequent consumption of quinolones and third-and fourth-generation cephalosporins in veterinary medicine has also been confirmed by the first joint report of the European Centre for Disease Prevention and Control (ECDC), the European Food Safety Authority (EFSA) and the EMA on antibiotics consumption and antibiotic resistance in humans and food-producing animals (Anon, 2015) . Converted to mg/ kg estimated biomass, the consumption in Germany of third-and fourth-generation generation cephalosporins by humans was higher than that in veterinary medicine by a factor of two, and the consumption of quinolones was higher than that in veterinary medicine by a factor of five. The causes that lead to high antibiotic use and an increasing percentage of reserve antibiotics prescriptions in human medicine in Germany have been summarized (Schr€ oder 2011b). The author identified an urgent need for better education and continuous training as approximately 50% of antibiotic prescriptions state wrong dosages and treatment durations. Moreover, up to 80% of antibiotic treatment courses for respiratory tract infections are incorrectly prescribed when the source is viral rather than bacterial infection. These principles can be considered to be relevant across Europe. It is obvious that, in veterinary medicine as well, the use of antibiotics should be limited to diagnostically proven bacterial infections that cannot be treated otherwise according to the state of scientific knowledge. Under no circumstances should antibiotics be used to compensate for deficits in hygiene and husbandry conditions. The general goal must be to establish a good antibiotic-administration practice both in human medicine and in veterinary medicine, on the principle 'as much as necessary, but as little as possible'.
Politics and science meet?
Even a cursory review of the published literature shows that laboratories around the world are continually identifying novel resistance genes or presenting first reports of existing resistance genes being found in different bacterial groups at an unprecedented rate; the advent of molecular technology has been a great help and we can without any doubt clearly say that we are good at detecting novel resistance genes. This, however, does not always seem to translate into concomitant increasing rates of resistance in, for example, food-borne pathogens. Interpretation of surveillance data has many challenges (Silley et al. 2011) and the purpose of this paper is not to consider the data in detail but considering the available European surveillance data (EFSA and ECDC (European Centre for Disease Prevention and Control) 2016) for Salmonella and Campylobacter, the two primary food-borne pathogens, we can draw some conclusions based on data for 2014, submitted by 28 EU Member States.
In Salmonella isolates from broilers, fattening turkeys and meat thereof, resistance to ampicillin, (fluoro)quinolones, tetracyclines and sulphonamides was frequently detected, whereas resistance to third-generation cephalosporins was uncommon. For the first time, presumptive extended-spectrum beta-lactamase (ESBL)-/AmpC-/carbapenemase production in Salmonella was monitored in poultry. While high resistance to ciprofloxacin and tetracyclines was observed in Campylobacter isolates from broilers and broiler meat, much lower levels were recorded for erythromycin. Coresistance to critically important antibiotics in both human and animal isolates was generally uncommon, but high multiple drug resistance was observed in some Salmonella serovars and a minority of Salmonella isolates from animals belonging to a few serovars (notably Kentucky and Infantis) exhibited high-level resistance to ciprofloxacin. In terms of the arguments being made in this paper the important point is that we are not seeing across Europe continually increasing antibiotic resistance rates in food-borne pathogens. Indeed the inclusion within the harmonized monitoring scheme of a supplementary panel of antibiotics, to be tested when certain resistances to an initial panel of antibiotics are detected, enabled detailed screening of resistance to three carbapenem compounds. No resistance to carbapenems was detected and this is a crucial finding, because carbapenems are critically important in human medicine. It must be noted, however, that carbapenemases have been detected in Enterobacteriaceae from food-producing animals in the EU, although the source of such resistance is not clear (Fischer et al. 2013) . The supplementary testing in the European surveillance also allowed, for the first time, detailed characterization of the beta-lactam resistance phenotypes occurring in Salmonella. The occurrence of ESBL-/AmpC-producers in Salmonella from poultry was assessed as being at low levels.
Considering the 'big picture' we would consequently conclude that there is something of a mismatch between the frequent reports of novel resistance genes and increasing prevalence of resistance, at the genetic level. While not many surveillance studies are published for target animal pathogens, the Vetpath surveillance programme (de Jong et al. 2013) suggests there is not a widespread resistance issue with veterinary pathogens (Thomas et al. 2015; El Garch et al. 2016) . We therefore suggest that our regulatory process is fit for purpose and does indeed approve products that are safe for use with regard to development of antimicrobial resistance. The primary objective of guidance CVMP/VICH/644/01-FINAL (Anon, 2004) is with regard to the characterization of the potential for a given antimicrobial agent to select for resistant bacteria of human health concern.
The way forward?
Within Guidance CVMP/VICH/644/01-FINAL (Anon, 2004 ) the sponsor is required to characterize the potential for the use of the product to select for antimicrobialresistant bacteria of human health concern. To accomplish this, the sponsor should discuss the data in terms of the exposure of food-borne pathogens and commensal organisms to a microbiologically active substance in the target animal after administration of the veterinary medicinal product under the proposed conditions of use. It is the last phrase that becomes crucial as we consider the whole concept of appropriate or prudent use of antibiotics. Indeed Guidance EMEA/CVMP/627/01-FINAL (Anon, 2016a) similarly addresses these issues; this is best summarized in section 7.2 "Dose-determination studies" of the guidance when it says, 'Regarding the dose level and the dosing interval, the PK and PD characteristics of the product should be considered to support the necessary exposure and consequently achieve a satisfactory balance between efficacy and risk for selecting for resistance'. We contend that current guidance is explicit with respect to addressing antimicrobial resistance and believe that surveillance data suggest the issues are not as pressing as some would have us believe, indicating the guidance is working. We do, however, need to improve surveillance and we need to continue to strengthen prudent use along the following lines.
Treatment rationale
Antibiotic treatment should only be based on an established diagnosis, consequently antibiotics should only be used after a bacterial disease is diagnosed. While this paper is addressing antibiotic use in veterinary medicine it becomes clear that in human and veterinary medicine, clear differential diagnostic decision trees must be developed, which include the degree of severity of the respective symptoms as a criterion for a treatment decision. There must also be a clear guideline for deciding what symptoms of a primary viral infection would indicate that a bacterial secondary infection requiring treatment should be considered.
There is a general consensus among scientists that antibiotics should not be used for trivial infections. Nonetheless, an antibiotic is often prescribed for risk mitigation. This is true both in human and veterinary medicine. The area of mild infections with high self-cure rates should also be covered by clear treatment guidelines and differential diagnostic decision trees. This approach should greatly reduce antibiotic use for such mild and transient infections.
Authorized indications
Once the diagnosis of a bacterial infection has been made, an appropriate antimicrobial in an appropriate formulation has to be chosen. The guiding principle must be that only those antibiotics are used that are authorized for the diagnosed indication and the bacteria involved. Only in justified exceptional cases, such as the presence of a life-threatening condition with no authorized product available, we should deviate from this principle. For veterinary medicines, the regulations on the treatment cascade set out in Directive 2001/82/EC, Articles 10 and 11 (Anon, 2001 ) must be followed. Combinations of different authorized products should only be administered in exceptional cases, when their benefit has been clearly scientifically proven in relevant publications.
The package insert represents the scientifically proven state of knowledge on the efficacy and safety of the antibiotic product, which is confirmed by the regulatory agency. Therefore, the instructions on the package insert should be strictly followed. This applies especially to the therapeutic indications, dosage, route of administration, treatment duration, warnings and contra-indications. Indeed, assessment of the antibiotic with regard to resistance development has been undertaken by the regulatory authorities on the basis of the labelled dose, as previously discussed; it is on this basis that a marketing authorization has been granted. Safety and efficacy have been demonstrated as a function of label instructions and, hence, any deviation from the label has the potential to introduce questions concerning the conclusions made regarding the development of antimicrobial resistance and public health.
There is a consequence to the above rationale, no antibiotic class should be excluded from use, thus arguing that there should not be defined formularies with regard to first-, second-and third-choice antibiotics. The veterinary expert decision should be based on the epidemiology of disease, pharmacology of the active substance, notably drug concentrations at the site of infection and observed treatment success rates. This implicitly argues that it is imperative to have an effective surveillance of the susceptibility of veterinary pathogens in Europe.
Susceptibility testing
While following the label indications must be mandatory it still becomes necessary to isolate the causative bacteria and carry out susceptibility testing so as to identify, on the basis of clinical breakpoints, the most appropriate antibiotic to use. Notwithstanding the need for susceptibility testing it is understood that for acute diseases requiring immediate treatment there will be a delay in availability of susceptibility test data; this emphasizes the importance of routine testing (surveillance) carried out for farm-specific pathogens for all relevant antibiotic classes on a regular basis throughout Europe.
This important issue does, however, hit something of an impasse with regard to the regulatory process. While all constituencies accept that antibiotic resistance is a significant issue we are faced with the reality that new antibiotics can receive a marketing authorization in Europe and indeed in the United States, without a sponsor having to generate a clinical breakpoint. The consequence of this is that for many antibiotics on the market we have no measure of what is resistant and what is susceptible to a given antibiotic at the approved or indeed the in use dose. Much of the debate on antimicrobial resistance within veterinary medicine is based on data sets that cannot stand up to independent scrutiny. This situation is all the more incredulous when we consider there are independent bodies that set clinical breakpoints in veterinary medicine, most notably the Subcommittee on Veterinary Antimicrobial Susceptibility Testing (VAST), part of the Clinical Laboratory Standards Institute (see, http://clsi. org/standards/micro/sub-vast/, accessed June 2017). Many of the recently approved antibiotics in Europe do have clinical breakpoints, this being as a result of responsible pharmaceutical companies independently taking data packages to VAST in order for VAST to independently set a clinical breakpoint.
We would argue that the time is right for all approvals of new or for existing antibiotics to have independently agreed clinical breakpoints, as part of the regulatory process. This is relevant not only for novel antibiotics but also for generic compounds, without which talk of resistance is somewhat meaningless. At this point it is pertinent to mention the case of plasmid-mediated resistance to colistin, and the need for valid breakpoints for the detection of resistance to this antibiotic. The present world-wide concern about the occurrence of colistin resistance following its detection in China and its apparent spread in food-producing animals, has been addressed by the EMA (Anon, 2016b) but we do not have meaningful clinical breakpoints.
Research efforts
In recent years and decades, countless publications have appeared on the occurrence of antibiotic resistance in bacteria from humans and animals, concerning the genetic basis and frequency of occurrence of resistance genes. While our knowledge of antibiotic resistance has greatly increased it is still difficult to transfer this knowledge to the epidemiology of antibiotic resistance, to say nothing of understanding of such complexity. In this regard, two publications of Sommer et al. (2009 Sommer et al. ( , 2010 are relevant. The authors researched the human microbiome with culture-independent functional-metagenomic methods, and identified a variety of new resistance genes in intestinal bacteria, which had not been possible to identify up to now in cultures of bacteria pathogenic to humans. One important conclusion of the authors was that there are obviously barriers to the lateral transfer of these resistance genes to bacteria pathogenic to humans. In order to better understand the transfer of resistance genes and its significance for the epidemiology of resistance, one possibility would be to concentrate research efforts on the actual event in the host organism (animal or human) with its complex communities of bacterial populations, instead of laboratory-based studies with pure cultures. It would consequently be desirable for human and veterinary medicine, in close collaboration with each other, to obtain a deeper knowledge of the genesis, dissemination and persistence of antibiotic resistance, in order to derive targeted measures, establish generally applicable principles for the responsible use of antibiotics and thereby retain these essential therapeutic agents for both areas in the long term.
Conclusions
The onerous regulation system has over the last 20 years rigorously addressed safety and efficacy of all veterinary medicines including antibiotics; this process has given focus to antibiotic resistance in the target pathogens and for food-producing animals in the food-borne pathogens and commensal flora, approving them as safe when used at the approved dose and against the label pathogens. We therefore question why there is any need to introduce additional restrictions. The veterinarian should be free to use 'Best in Class' antibiotics as a first-line response to treat infectious disease as medicines approval has shown the drug to be safe and efficacious.
We contend that the current regulatory guidelines do provide for approval of safe and efficacious antibiotics and that this is supported by our assertion that the increasing number of detected resistance genes does not necessarily translate into increased clinical resistance rates in veterinary practice. In order to safeguard the future utility of antibiotics for treatment of bacterial infections, both in animals and humans, prudent use centred on correct diagnosis, correct choice and use of the antimicrobial along with appropriate susceptibility testing needs to be strengthened.
We must always be mindful of the challenges posed by antibiotic resistance, consequently, we strongly believe that the setting of clinical breakpoints should be made mandatory for all novel antibiotics, without clinical breakpoints any discussion on resistance becomes somewhat meaningless and clinical resistance cannot be measured. As we seek to further understand the spread of antibiotic resistance it is crucial that surveillance programmes based on agreed criteria are implemented for animal pathogens; this would be best directed jointly by the regulatory authorities and industry.
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